<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04645199</url>
  </required_header>
  <id_info>
    <org_study_id>IHBDH-IIT2020025</org_study_id>
    <nct_id>NCT04645199</nct_id>
  </id_info>
  <brief_title>National Longitudinal Cohort of Hematological Diseases</brief_title>
  <acronym>NICHE</acronym>
  <official_title>National Longitudinal Cohort of Hematological Diseases (NICHE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background Hematological diseases are disorders of the blood and hematopoietic organs. The&#xD;
      current hematological cohorts are mostly based on single-center or multi-center cases, or&#xD;
      cohorts with limited sample size in China. There is a lack of comprehensive and large-scale&#xD;
      prospective cohort studies in hematology. The purpose of this study is to analyze the&#xD;
      incidence and risk factors of major blood diseases, the treatment methods, prognosis and&#xD;
      medical expenses of these patients in China.&#xD;
&#xD;
      Method The study will include patients diagnosed with acute myeloid leukemia, multiple&#xD;
      myeloma, or hemophilia in the investigating hospitals from January 1, 2020, and collect basic&#xD;
      information, diagnostic and treatment information, as well as medical expense information&#xD;
      from medical records. The study will use questionnaire to measure the exposure of patients,&#xD;
      and prospectively follow-up to collect the prognosis information.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and distribution</measure>
    <time_frame>5 years</time_frame>
    <description>To describe the incidence and population characteristics of acute myeloid leukemia, multiple myeloma, and hemophilia in China, and analyze the risk factors associated with these diseases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutic evaluation</measure>
    <time_frame>5 years</time_frame>
    <description>To analyze the therapeutic efficacy and long-term prognosis of patients with acute myeloid leukemia, multiple myeloma, and hemophilia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic evaluation</measure>
    <time_frame>5 years</time_frame>
    <description>To conduct health economic evaluation on patients with acute myeloid leukemia, multiple myeloma, and hemophilia.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2300</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Myeloma, Multiple</condition>
  <condition>Myelomas, Multiple</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Leukemias, Acute Myeloid</condition>
  <condition>Myeloid Leukemias, Acute</condition>
  <condition>Hemophilia</condition>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <condition>Hemophilia Bs</condition>
  <condition>Bs, Hemophilia</condition>
  <condition>Hemophilia As</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were diagnosed with acute myeloid leukemia, multiple myeloma or hemophilia in&#xD;
        the investigating hospitals from January 1, 2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who were diagnosed with acute myeloid leukemia, multiple myeloma or&#xD;
             hemophilia in the investigating hospitals from January 1, 2020.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Long-term follow-up information for patients is not available for any reason, such as&#xD;
             not being available or having a serious concomitant disease.&#xD;
&#xD;
          -  Alcohol and drug addictions affect their ability to comply with study requirements.&#xD;
&#xD;
          -  According to the investigator, there are conditions that may endanger the patient's&#xD;
             safety or affect his/her compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhen Song, MD</last_name>
    <phone>+86 02223909051</phone>
    <email>cir@ihcams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen Song, MD</last_name>
      <phone>022-23909051</phone>
      <email>songzhen@ihcams.ac.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Chengtao</investigator_full_name>
    <investigator_title>Director of Institute of Hematology &amp; Blood Diseases Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: NICHE-AML</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT04645199/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: NICHE-MM</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT04645199/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: NICHE-Hemophilia</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 27, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT04645199/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: NICHE-AA</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT04645199/Prot_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

